Spur Therapeutics on Tuesday said it has treated the first Gaucher disease patient with its investigational gene therapy, FLT201 (avigbagene parvec), in a pivotal trial. In the Phase III GALILEO-3 ...
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
In a Phase III trial, divarasib bested first-generation drugs Lumakras and Krazati, which the firm said could make it a new standard of care in KRAS G12C-mutated NSCLC.
The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.
NEW YORK – The European Commission has approved Novartis' gene therapy Itvisma (onasemnogene abeparvovec) for patients at least two years old with 5q-associated spinal muscular atrophy (SMA) and ...
The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results